Outcomes pre-HUGO and post-HUGO guideline implementation
| 2011 (n=115) | 2013 (n=165) | p Value | |
| Treatment* and test† (n (%)) | 52/115 (45) | 25/165 (15) | <0.001 |
| At least one treatment* (n (%)) | 52/115 (45) | 46/165 (28) | 0.003 |
| At least one test† (n (%)) | 101/115 (88) | 52/165 (32) | <0.001 |
| CXR (n (%)) | 99/115 (86) | 44/165 (27) | <0.001 |
| RSV nasopharyngeal swabs (n (%)) | 28/115 (24) | 26/165 (16) | 0.073 |
| Inflammatory blood test (n (%)) | 34/115 (30) | 18/165 (11) | <0.001 |
| Antibiotic use (n (%)) | 44/115 (38) | 22/165 (13) | <0.001 |
| Salbutamol use >1 dose (n (%)) | 9/115 (8.0) | 8/165 (5.0) | 0.21 |
| Corticosteroid use (n (%)) | 12/115 (10) | 5/165 (3.0) | 0.011 |
| Chest physiotherapy (n (%)) | 7/115 (6.1) | 1/165 (0.6) | 0.009 |
| Nasogastric fluid replacement (n (%)) | 19/115 (17) | 58/165 (35) | <0.001 |
| Nasogastric feed length, day, median (IQR) | 1.5 (1.0–3.0) | 2.0 (1.0–3.0) | 0.70 |
| Intravenous fluid replacement (n (%)) | 25/115 (22) | 22/165 (13) | 0.064 |
| Intravenous hydration length, day, median (IQR) | 1.0 (1.0–1.5) | 1.5 (0.5–2.0) | 0.59 |
| Oxygen use (n (%)) | 71/115 (62) | 83/165 (50) | 0.058 |
| O2 max, L/min, median (IQR) | 0.5 (0.25–1) | 0.5 (0.5–1) | 0.67 |
| Oxygen duration, day, median (IQR) | 2.0 (1.0–2.5) | 2.0 (1.5–3.0) | 0.10 |
| % Amoxicillin in ATB (n (%)) | 9/44 (20) | 19/22 (86) | <0.001 |
| % Amoxicillin-clavulanate in ATB (n (%)) | 28/44 (64) | 1/22 (4.5) | <0.001 |
| LOS in general paediatric wards, day, median (IQR) | 2.0 (1.5–3.0) | 2.0 (1.5–3.0) | 0.28 |
| ICU transfer (n (%)) | 8/115 (7) | 7/165 (4.2) | 0.23 |
| All-cause 7-day readmission (n (%)) | 5/115 (4.4) | 7/156 (4.2) | 0.59 |
*Treatment among antibiotics/salbutamol/corticosteroids.
†Test among CXR/blood test/RSV test.
ATB, antibiotic prescription; CXR, chest X-ray; ICU, intensive care unit; RSV, respiratory syncytial virus.